Cancer – BrainChild-02: Phase 1 Study of EGFR806-Specific CAR T-Cell Locoregional Immunotherapy for EGFR-Positive Recurrent or Refractory Pediatric Central Nervous System Tumors
Condition or Therapy:
EGFR-positive recurrent or refractory brain and central nervous system (CNS) tumors
What is the goal of this study?
Seattle Children’s is recruiting patients for a phase 1 clinical trial that is testing CAR T-cell therapy in children and young adults with recurrent or refractory brain and central nervous system (CNS) tumors who are not likely to survive with standard treatments.
With this trial, researchers are working to answer these questions:
- Is this T-cell therapy safe to give to children and young adults with recurrent or refractory EGFR-positive CNS tumors?
- What is the best dose of this therapy?
Who can join the study?
This study might be a good fit for children and young adults who:
- Are ages 1 to 26 years old
- Have recurrent or refractory CNS tumors that express the protein EGFR
Researchers use many other factors to decide whether or not a patient can take part in a study (called inclusion and exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
In this study, the patients own T cells will be reprogrammed to recognize and target the EGFR protein, which is found on many pediatric brain tumors but not healthy brain tissue.
The reprogrammed cells will be put back into your body (infused) through a catheter, either into the place where a tumor was removed or into the CNS ventricular system (intra-CNS). Placement of this catheter will depend on the location of your tumor.
Read more about the BrainChild-02 study at clinicaltrials.gov.
Who can I contact for more information?
For more information, please call 206-987-2106 or send us an email.